Quest Diagnostics

Quest Study: Looser Criteria Double Primary Aldosteronism Detection

Image
Quest Study: Looser Criteria Double Primary Aldosteronism Detection

Secaucus – October 19, 2026 -- A broader set of lab criteria identified primary aldosteronism (PA) in 26.2% of 60,449 U.S. patients, twice the 13.0% flagged under the Endocrine Society's 2025 guidelines, according to a Quest Diagnostics (NYSE: DGX) study published in the journal Hypertension.

Study compares 2025 guideline cutoffs with a permissive threshold

Researchers from Quest Diagnostics, Mass General Brigham, Harvard Medical School and the University of Texas Southwestern Medical School analyzed deidentified Quest lab results. The 2025 criteria require plasma renin activity (PRA) of 1 ng/mL/h or lower, aldosterone of at least 7.5 ng/dL and an aldosterone-to-renin ratio (ARR) above 15. The permissive criteria keep the PRA limit, set aldosterone above 5 ng/dL and drop the ARR requirement.

The authors describe the 2025 guidelines as "overly restrictive," with cutoffs that capture only the most advanced cases.

Survey: 75% of Voters Urge Congress to Halt 2027 Medicare Lab Cuts

Secaucus, N.J. – September 19, 2026 -- A new national survey commissioned by Quest Diagnostics (NYSE: DGX) finds that 75% of 1,024 registered voters surveyed consider diagnostic lab testing "very important" to their care, with a bipartisan majority pressing Congress to pass the RESULTS Act before scheduled Medicare payment cuts take effect September 19, 2026.

83% of voters relied on a lab test in the past two years to guide a medical decision

The survey found 96% of registered voters view diagnostic lab tests as important to their or their family's care, while 88% expressed concern if Medicare lab payment rates were set too low. Half of respondents said Medicare seniors, rural communities, and people managing cancer or chronic disease would be hurt most if the cuts take effect.